Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)
The COPCOV trial will determine whether a daily prophylactic dose of chloroquine / hydroxychloroquine can protect healthcare workers from catching COVID-19 infection
Chloroquine and hydroxychloroquine have been used for over 50 years to prevent and treat malaria and to treat rheumatoid arthritis. They have an excellent safety profile making them potentially suitable for mass use as prophylaxis and in many laboratory studies they have antiviral activity. We are conducting a study to find out whether chloroquine and hydroxychloroquine may prevent people catching coronavirus. We will also find out if taking these drugs at the time people catch coronavirus may also mean they become less sick.
This website contains information about the COPCOV study in the UK. Information about the global study can be found here. Following approval from the Medicines and Healthcare Regulatory Agency COPCOV is now open to recruitment again. Interested participants should complete a registration form and we will contact them as soon as possible.
Current UK recruitment sites:
- Brighton and Sussex University Hospitals NHS Trust
- Oxford University Hospitals NHS Trust
- Imperial College Healthcare NHS Trust
- University Hospitals Coventry and Warwickshire NHS Trust
- University Hospitals of Morecambe Bay NHS Trust
Current recruitment count in the UK:
166
For Participants
Details about the study can be found here in the study Participant Information Sheet (PIS)
For study sites
Key study documents and information for sites running COPCOV in the UK